QuickView for Josamycin (compound)

Summary
General Info

PubChem

PubChem Compound 3804

Name:	Josamycin
PubChem Compound ID:	3804
Description:	A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
Molecular formula:	C₄₂H₆₉NO₁₅
Molecular weight:	827.995 g/mol

DrugBank

Identification

Name:	Josamycin
Name (isomeric):	DB01321
Drug Type:	small molecule
Description:	A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
Synonyms:	JM; Leucomycin V, 3-acetate 4B-(3-methylbutanoate); Josamycine [inn-french]; Josamicina [inn-spanish]; Leucomycin V, 3-acetate 4(sup beta)-(3-methylbutanoate); Antibiotic yl-704 A3; Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); Leucomycin A3; Josamycinum [inn-latin]
Brand:	Kitasamycin A3, Turimycin A5, Josacine
Category:	Anti-Bacterial Agents, Antibacterial Agents, Macrolides
CAS number:	16846-24-5

Pharmacology

Indication:	For the treatment of bacterial infections.
Pharmacology:	Josamycin is a macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
Mechanism of Action:	The mechanism of action of macrolides such as Josamycin is via inhibition of bacterial protein biosynthesis by binding reversibly to the subunit 50S of the bacterial ribosome, thereby inhibiting translocation of peptidyl tRNA. This action is mainly bacteriostatic, but can also be bactericidal in high concentrations. Macrolides tend to accumulate wi... show more » The mechanism of action of macrolides such as Josamycin is via inhibition of bacterial protein biosynthesis by binding reversibly to the subunit 50S of the bacterial ribosome, thereby inhibiting translocation of peptidyl tRNA. This action is mainly bacteriostatic, but can also be bactericidal in high concentrations. Macrolides tend to accumulate within leukocytes, and are therefore actually transported into the site of infection. show less «
Affected organisms:	Enteric bacteria and other eubacteria

Interactions

Drug interaction:

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Itraconazole	The macrolide, josamycin, may increase the effect and toxicity of itraconazole.
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Digoxin	The macrolide, josamycin, may increase the effect of digoxin in 10% of patients.
Cyclosporine	The macrolide, josamycin, may increase the effect of cyclosporine.

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Itraconazole	The macrolide, josamycin, may increase the effect and toxicity of itraconazole.
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Digoxin	The macrolide, josamycin, may increase the effect of digoxin in 10% of patients.
Cyclosporine	The macrolide, josamycin, may increase the effect of cyclosporine.
Docetaxel	Josamycin may increase the serum levels and toxicity of docetaxel.
Divalproex sodium	Erythromycin increases the effect of valproic acid
Methysergide	Possible ergotism and severe ischemia with this combination
Diazepam	The macrolide, josamycin, may increase the effect of the benzodiazepine, diazepam.
Carbamazepine	The macrolide, josamycin, may increase the effect of carbamazepine.
Dihydroergotamine	Possible ergotism and severe ischemia with this combination
Buspirone	The macrolide, josamycin, may increase the effect and toxicity of buspirone.
Triazolam	The macrolide, josamycin, may increase the effect of the benzodiazepine, triazolam.
Mesoridazine	Increased risk of cardiotoxicity and arrhythmias
Cerivastatin	The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin.
Cilostazol	Erythromycin increases the effect of cilostazol
Atorvastatin	The macrolide, josamycin, may increase the toxicity of the statin, atorvastatin.
Fluoxetine	Possible serotoninergic syndrome with this combination
Thioridazine	Increased risk of cardiotoxicity and arrhythmias
Pimozide	Increased risk of cardiotoxicity and arrhythmias
Theophylline	The macrolide, josamycin, may increase the effect and toxicity of theophylline.
Clozapine	Erythromycin increases the effect of clozapine
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Lovastatin	The macrolide, josamycin, may increase the toxicity of the statin, lovastatin.
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Aminophylline	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
Moxifloxacin	Increased risk of cardiotoxicity and arrhythmias
Repaglinide	The macrolide, josamycin, may increase the effect of repaglinide.
Oxtriphylline	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
Citalopram	Possible serotoninergic sydrome with this combination
Alprazolam	The macrolide, josamycin, may increase the effect of the benzodiazepine, alprazolam.
Rifampin	The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin.
Midazolam	The macrolide, josamycin, may increase the effect of the benzodiazepine, midazolam.
Ergotamine	Possible ergotism and severe ischemia with this combination
Imatinib	The macrolide, josamycin, may increase the serum concentration of imatinib.
Felodipine	Erythromycin increases the effect of felodipine
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Bromocriptine	Erythromycin increases serum levels of bromocriptine
Rifabutin	The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin.

show less «

Targets

50S ribosomal protein L4

Enzymes

Cytochrome P450 3A4